Literature DB >> 15844952

The psammaplysenes, specific inhibitors of FOXO1a nuclear export.

Frank C Schroeder1, Tweeny R Kau, Pamela A Silver, Jon Clardy.   

Abstract

A small collection of marine natural product extracts was screened for compounds that would compensate lost tumor suppressor functionality in PTEN-deficient cells. From the most active extract, the previously unreported bromotyrosine derivative, psammaplysene A (1), was identified. Psammaplysene A compensates for PTEN loss by relocalizing the transcription factor FOXO1a to the nucleus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15844952     DOI: 10.1021/np049624z

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  21 in total

1.  Preparation of a psammaplysene-based library.

Authors:  Savvas N Georgiades; Jon Clardy
Journal:  Org Lett       Date:  2006-09-14       Impact factor: 6.005

2.  Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1.

Authors:  Emily Berry; Jennifer L Hardt; Jon Clardy; John R Lurain; J Julie Kim
Journal:  Gynecol Oncol       Date:  2008-11-28       Impact factor: 5.482

3.  FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases.

Authors:  Jelena Mojsilovic-Petrovic; Natalia Nedelsky; Marco Boccitto; Itzhak Mano; Savvas N Georgiades; Weiguo Zhou; Yuhong Liu; Rachael L Neve; J Paul Taylor; Monica Driscoll; Jon Clardy; Diane Merry; Robert G Kalb
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

4.  Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension.

Authors:  Rajkumar Savai; Hamza M Al-Tamari; Daniel Sedding; Baktybek Kojonazarov; Christian Muecke; Rebecca Teske; Mario R Capecchi; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph Theo Schermuly; Soni Savai Pullamsetti
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

Review 5.  Deciphering the role of forkhead transcription factors in cancer therapy.

Authors:  Jer-Yen Yang; Mien-Chie Hung
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

6.  FOXO1: a potential target for human diseases.

Authors:  Huarui Lu; Haojie Huang
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

Review 7.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

8.  FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells.

Authors:  Silvia Fernández de Mattos; Priam Villalonga; Jon Clardy; Eric W-F Lam
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 9.  A new fork for clinical application: targeting forkhead transcription factors in cancer.

Authors:  Jer-Yen Yang; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 10.  Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.

Authors:  Alejandro M S Mayer; Kirk R Gustafson
Journal:  Eur J Cancer       Date:  2008-08-11       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.